Literature DB >> 21745274

Hepatitis C virus infection in USA: an estimate of true prevalence.

Eric Chak1, Andrew H Talal, Kenneth E Sherman, Eugene R Schiff, Sammy Saab.   

Abstract

The recent National Health and Nutrition Examination Survey (NHANES) sampled only the civilian, non-institutionalized population of USA and may have underestimated the prevalence of hepatitis C virus (HCV) in this country. We searched the database MEDLINE, the Bureau of Justice Statistics, Center for Medicare and Medicaid and individual states Department of Corrections for all epidemiological studies regarding the prevalence of HCV in populations not sampled by the NHANES survey namely the incarcerated, homeless, nursing home residents, hospitalized and those on active military duty. Because of their relatively low frequency in the NHANES sample, we also expanded our search to include healthcare workers and long-term dialysis patients. Although included in the NHANES sample, we also performed searches on drug users (injection and non-injection) and veterans to confirm the findings of the NHANES study. Based on the prevalence of studies identified meeting our inclusion criteria, our most conservative estimates state that there at least 142,761 homeless persons, 372,754 incarcerated persons and 6805 persons on active military duty unaccounted for in the NHANES survey. While the NHANES estimates of drug users (both injection and non-injection) appear to be reasonable, the survey seems to have underestimated the number of HCV-positive veterans. Our most conservative estimates suggest that there are at least 5.2 million persons living with HCV in USA today, approximately 1.9 million of whom were unaccounted for in the NHANES survey.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21745274     DOI: 10.1111/j.1478-3231.2011.02494.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  162 in total

1.  Survey of US Correctional Institutions for Routine HCV Testing.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri Bazerman; Liza Solomon; Emily Patry; Josiah D Rich; Irene Kuo
Journal:  Am J Public Health       Date:  2015-01       Impact factor: 9.308

2.  Recent advances in management of the HIV/HCV coinfected patient.

Authors:  Cindy J Bednasz; Joshua R Sawyer; Anthony Martinez; Patrick G Rose; Samantha S Sithole; Holly R Hamilton; Farzia S Kaufman; Charles S Venuto; Qing Ma; Andrew Talal; Gene D Morse
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 3.  Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Authors:  Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson
Journal:  Hepatology       Date:  2018-11-06       Impact factor: 17.425

4.  Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.

Authors:  Aiden K Varan; Daniel W Mercer; Matthew S Stein; Anne C Spaulding
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

5.  Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.

Authors:  Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Pat Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg
Journal:  Public Health Rep       Date:  2018-05-11       Impact factor: 2.792

6.  Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens.

Authors:  E Kainne Dokubo; Jennifer Evans; Valerie Winkelman; Sherri Cyrus; Leslie H Tobler; Alice Asher; Alya Briceno; Kimberly Page
Journal:  J Clin Virol       Date:  2014-01-27       Impact factor: 3.168

7.  Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Authors:  Andrew H Talal; Rositsa B Dimova; Eileen Z Zhang; Min Jiang; Marina S Penney; James C Sullivan; Martyn C Botfield; Ananthsrinivas Chakilam; Rishikesh Sawant; Christine M Cervini; Marija Zeremski; Ira M Jacobson; Ann D Kwong
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

8.  Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.

Authors:  Bevin Hearn; David Delbello; Joseph Lawler; Michel Ng; Alyson Harty; Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

9.  Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.

Authors:  Naina Barretto; Bruno Sainz; Snawar Hussain; Susan L Uprichard
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 10.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Authors:  Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.